← All trials
NCT00554463
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2008
- Primary completion
- Aug 1, 2011
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Radiation Therapy Oncology GroupLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of Texas at HoustonStudy chair
- Duke UniversityStudy chair
- Icahn School of Medicine at Mount SinaiStudy chair
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Cancer and Leukemia Group B (CALGB)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.